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Abstract 
A retrospective treated vs untreated study (study one) and multi-centre prospective cohort 
study (study two) were undertaken to determine the prevalence of, and risk factors 
associated with, acute laminitis in horses treated with corticosteroids. All horses >1 year old 
treated with corticosteroids January to December 2014 (study one) and January 2015 to 
February 2017 (study two) by two first opinion and referral hospitals in UK were included. 
Additionally, an untreated animal was identified for each treated animal (study one). 
Signalment, body condition (Study two only), previous relevant medical history, primary 
condition, corticosteroid therapy prescribed and occurrence of acute laminitis during or 
within 14 days of cessation of corticosteroid treatment were recorded. For study one, 205 
cases and 205 controls were identified; two animals within each group (1%) developed 
laminitis. In total, 1565 animals were included in study two; laminitis period prevalence was 
0.6% (95% CI 0.4-1.2%), with 10 cases in 1565 treated animals. There were significant 
associations between laminitis and breed (pony vs horse; p=0.01; univariable analysis only), 
the presence of a laminitis risk factor (history of laminitis or an underlying endocrinopathy; 
p<0.001; OR [95% CI] 18.23 [5.05-65.87]) and body condition (overweight/obese vs not; 
p=0.04; OR [95% CI] 4.0 [1.09-14.75]).  
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Introduction 
Corticosteroids are used in clinical practice to treat a range of non-infectious inflammatory 
diseases affecting horses. Since their introduction to veterinary therapeutics over 40 years 
ago, they have been associated with a perceived increased risk of acute laminitis (Bailey and 
Elliott 2007; Cornelisse and Robinson 2004; Cornelisse and Robinson 2013). However, there 
is little scientific evidence to support this association in healthy animals (McGowan and others 
2016) and direct causation has not been established (Bailey 2010). 
 
There are several published case reports involving either single or small number of animals 
treated with corticosteroids that developed laminitis (Cohen and Carter 1992; Dutton 2007; 
Frederick and Kehl 2000; Lose 1980; Ryu and others 2004; Vandenabeele and others 2004; 
Winfield and others 2013). However, many of these animals had pre-existing laminitis risk 
factors. Indeed, a study of electronic medical records identified corticosteroid use 
(prednisolone only) as a risk factor associated with subsequent, but not initial, laminitis 
episodes (Welsh and others 2017). There have been five case control studies published. One 
prospective study evaluated the treatment of severe equine asthma with dexamethasone and 
2/25 (8%) animals developed laminitis (Muylle and Oyaert 1973). In two retrospective case 
control studies of laminitis, 3/108 (3%) cases had a history of prior treatment with 
corticosteroids in the first study (Slater and others 1995) and no association with recent 
corticosteroid use was identified in the second study (Wylie and others 2013b). A 
retrospective case-control study of animals treated with prednisolone revealed that 
prednisolone therapy was not associated with an increase in laminitis incidence (Jordan and 
others 2017). Finally, a prospective case-control study of pasture and endocrinopathy-
associated laminitis (PEAL) revealed a 5.7-fold greater odds of PEAL among horses that had 
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received corticosteroids within the 30 days prior to examination relative to control (healthy 
and lameness combined) horses that had not (Coleman and others 2018). However, prior 
corticosteroid use did not remain in the final multivariable model comparing PEAL cases to 
lameness controls alone or to healthy controls alone, suggesting that the association could 
have been confounded by another variable (Coleman and others 2018). More importantly, 
corticosteroid administration was uncommon in all groups of horses (Coleman and others 
2018). 
 
Other relevant studies include two retrospective reviews of laminitis in which 4/216 (1.9%) 
cases (Cripps and Eustace 1999) and 8/525 (1.5%) cases (Hood and others 1993) of laminitis 
were associated with corticosteroid therapy. In addition, in three retrospective reviews of 
cases treated with triamcinolone, 3/2000 (0.15%) (Bathe 2007), 1/205 (0.5%) (McCluskey and 
Kavenagh 2004) and 20/27898 (0.07%) (Hammersley and others 2015) animals treated with 
triamcinolone developed laminitis. In this last study, the risk of developing laminitis was 
significantly higher in the control population (Hammersley and others 2015). Adverse drug 
reaction reports from USA recorded only 19 cases of laminitis associated with corticosteroid 
therapy between 1987 and 2013 (i.e. 30 years; (USDA-NAHMS 2000). Finally, there have been 
several publications documenting high doses or long courses of corticosteroid treatment with 
no subsequent laminitis development (French and others 2000; Lepage and others 1993; 
Tumas and others 1994).  
 
The aims of this study were to determine the prevalence of, and the risk factors associated 
with, acute laminitis in a population of adult horses treated with corticosteroids.  
 
 5 
Materials and Methods  
The study was approved by the Royal Veterinary College Clinical Research Ethical Review 
Board (URN 2014 1309). 
 
Study one: Retrospective treated vs untreated study 
The clinical database of the Royal Veterinary College equine hospital and first opinion practice 
were searched to identify all horses ≥1 year old that had been treated with corticosteroids 
between 1st January 2014 and 31st December 2014. Untreated animals were identified as an 
animal seen on the same day and by the same veterinarian as a treated animal. A random 
number generator was used to select the untreated animal if more than one suitable animal 
existed. Exclusion criteria included corticosteroid treatment or laminitis in the preceding 28 
days and euthanasia or death in the first 14 days post corticosteroid treatment not 
attributable to laminitis. For all animals, the age, breed, sex, previous relevant medical history 
and whether the horse developed laminitis in the 14-day period immediately after treatment 
were recorded. The type, route, dose and duration of corticosteroid was recorded for treated 
animals. 
 
Study two: Multi-centre prospective cohort study   
All horses ≥1 year old treated with corticosteroids between January 2015 and February 2017 
by Royal Veterinary College and Bell Equine first opinion equine practices and referral 
hospitals were included in a prospective cohort study. Exclusion criteria included 
corticosteroid treatment or laminitis in the preceding 28 days and euthanasia or death in the 
first 14 days post corticosteroid treatment not attributable to laminitis. The age, breed, sex, 
subjective assessment of body condition (underweight, ideal, overweight or obese), previous 
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relevant medical history, current medical problem being treated, corticosteroid therapy 
prescribed (type, route, dose and duration) and the occurrence of acute laminitis during or 
within the first 14 days following the cessation of corticosteroid treatment were recorded by 
the treating veterinarian using a standard recording form (supplementary information 1).  
 
A sample size calculation assuming 80% power and 95% confidence, based on a previous 
study in which the prevalence of laminitis was 4% (Menzies-Gow and others 2017) indicated 
that 1060 animals were required. The sample size calculation was subsequently re-calculated, 
as the period prevalence of corticosteroid-associated laminitis after one year of data 
collection was 0.7%; this indicated that 1553 animals were required for study two. 
 
Data analysis 
Statistical analyses were performed using commercial statistical software (IBM SPSS Statistics 
Version 23 and Graphpad Prism Version 7). Continuous data was tested for normality using 
the Shapiro-Wilk test.. 
 
Study one: Retrospective treated vs untreated study 
The treated and untreated groups were compared using an unpaired student t-test (age) and 
Chi-squared tests (breed and sex). Significance was accepted at p≤0.05. No further 
comparisons were appropriate as an identical number of animals within each group 
developed laminitis. 
 
Study two: Multi-centre prospective cohort study   
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Laminitis period prevalence was calculated as the proportion of the population that 
developed laminitis during or within 14 days following cessation of corticosteroid treatment, 
over the 25-month period of data collection. Individual factors significantly associated with 
laminitis development (age, breed [pony or horse], sex, veterinary practice [first opinion or 
referral], presence of a laminitis risk factor [previous laminitis or an underlying endocrine 
disease], body condition [underweight, ideal, overweight or obese], corticosteroid 
preparation [active ingredient], route of administration [systemic, intrasynovial, local 
infiltration or inhaled], dose, duration or condition requiring treatment) were initially 
determined using univariable analysis. Significance was accepted at p≤0.1. Multivariable 
binary logistic regression with backwards-stepwise selection was then performed in order to 
determine the likelihood of these individual significant factors being associated with the 
development of laminitis, with only variables with p≤0.05 being retained in the final model. 
Interactions between risk factors were also tested. Interactions between risk factors were 
tested by calculating A*B for significant risk factors and entering A*B into the multivariable 
model. If the P value for the interaction term A*B was >0.05, there was no significant 
interaction between risk factors A and B and they were sequentially removed until all the risk 
factors had P values of ≤0.05 in the final model. The odds ratio (OR) and 95% confidence 
intervals were calculated for significant variables. 
 
Results 
Study one: Retrospective treated vs untreated study 
In total, 205 treated and 205 untreated animals were included in the study. The treated 
animals were significantly (p=0.02) older (median 13 [interquartile range, 9 - 17] years) than 
the untreated animals (11 [6.75 – 17] years). The untreated group comprised a significantly 
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(p=0.03) greater proportion of mares (45%) compared to the treated group (33%). The breed 
distributions were similar between the two groups. Within the treated group, 42% were non-
Thoroughbred horses, 28% were ponies, 16% were Thoroughbreds and 14% were of unknown 
breed. Within the untreated group, 41% were non-Thoroughbred horses, 34% were ponies, 
19% were Thoroughbreds and 7% were of unknown breed.  
 
The most common reasons for corticosteroid treatment were musculoskeletal problems and 
lameness (46%), followed by skin problems (22%) and respiratory problems (18%).  
Dexamethasone was the most frequently administered corticosteroid (51%), followed by 
triamcinolone acetonide (15%), methylprednisolone acetate (13%) and prednisolone (11%). 
Inhaled preparations were infrequently prescribed; beclamethasone (6%) and fluticasone 
(1%).  The duration of therapy varied from a single administration to 4 weeks. All animals 
received doses that were within the recommended ranges for horses. 
 
Two animals (2/205; 1%) within each group developed laminitis. The laminitis could not be 
attributed to sepsis/systemic inflammation or supporting limb lameness in any animal. Out of 
the two treated animals that developed laminitis, one was treated with dexamethasone and 
one was treated with both dexamethasone and prednisolone, and neither had any relevant 
previous medical conditions. Both untreated animals had a history of previously laminitis and 
one also had equine metabolic syndrome (EMS). 
 
Study two: Multi-centre prospective cohort study   
In total, 1565 animals were included in the study, of which 36.9% were mares, 60.8% geldings 
and 2.3% stallions, aged (median [interquartile range]) 11 (7-16) years. Of these, 55.8% were 
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non-thoroughbred horses, 25.9% Thoroughbreds, and 18.3% ponies. Subjective assessment 
of body condition considered 7.4% as underweight, 70.1% as ideal body condition, 20.3% as 
overweight and 2.2% as obese. In addition, 10.1% of animals had a laminitis risk factor 
present, namely a history of previous laminitis or an endocrine disease (equine metabolic 
syndrome or pituitary pars intermedia dysfunction [PPID]). Finally, 693 (44%) were treated by 
an equine referral hospital and 872 (56%) by a first opinion equine practice. 
 
In total, 45.6% of animals were treated for orthopaedic disease and 54.4% were treated for 
other medical conditions. Furthermore, 50.5% of animals received the corticosteroids 
systemically, 34.5% via the intra-synovial route, 10.7% via local infiltration and only 4.3% via 
inhalation. Dexamethasone was the most frequently administered corticosteroid (41.0%), 
followed by triamcinolone acetonide (28.0%), methylprednisolone acetate (16.7%) and 
prednisolone (10.1%). Inhaled preparations were infrequently prescribed; beclamethasone 
(3.6%) and fluticasone (0.6%). The duration of therapy varied from a single administration to 
daily therapy for 3 months. All animals received doses that were within the recommended 
ranges for horses. 
 
The period prevalence of laminitis was 0.6% (95% CI 0.4-1.2%), with 10/1565 animals treated 
with corticosteroids developing laminitis. The laminitis could not be attributed to 
sepsis/systemic inflammation or supporting limb lameness in any animal. Of these ten 
animals, three (30.0%) were treated for orthopaedic disease and seven were treated for other 
medical conditions; seven received systemic therapy (4 dexamethasone plus prednisolone, 
three only prednisolone) with the remaining three receiving intra-synovial medication (2 
triamcinolone acetonide and 1 methylprednisolone); seven were euthanased, of which this 
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was due to laminitis severity or failure of the laminitis to respond to conservative treatment 
in four animals and due to deterioration of the primary disease in three animals.  
Univariable analysis revealed significant associations between laminitis development and 
breed (horse vs pony; p=0.01), body condition (overweight/obese vs not; p=0.03) and the 
presence of a pre-existing laminitis risk factor (history of laminitis or an underlying 
endocrinopathy vs not; p<0.001). There was no significant association with age, practice, 
corticosteroid preparation, route of administration, dose, duration or condition requiring 
treatment. Multivariable analysis revealed significant associations between laminitis and the 
presence of a laminitis risk factor and an overweight/obese body condition (Table 1). Breed 
was not retained in the final model. In addition, there were significant interactions between 
three risk factors: between breed and body condition (p<0.001); between breed and presence 
of a laminitis risk factor (p<0.001); and between presence of a laminitis risk factor and body 
condition (p=0.003). 
 
Discussion  
The occurrence of laminitis in animals treated with corticosteroids was low in both studies 
(0.6-1.0%) and was similar to the frequency of veterinary-diagnosed laminitis reported in the 
GB general equine population of 0.5% (Wylie and others 2013a) and that in the untreated 
population in study one. Previously, a data mining study identified 0.07% of 27,898 
triamcinolone-treated horses developed laminitis compared to 0.2% in the untreated control 
population (Hammersley and others 2015). Similarly, whilst 3.9% of animals treated with 
enteral prednisolone developed laminitis, this incidence rate was not different to that within 
the control untreated group (Jordan and others 2017). Thus, it would appear that laminitis 
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does not occur more frequently in populations of animals treated with corticosteroids than 
in the general equine population. 
 
Univariable analysis revealed significant associations between the development of laminitis 
in animals treated with corticosteroids and breed (pony), body condition (overweight/obese) 
and the presence of a pre-existing laminitis risk factor (endocrine disease or a history of 
laminitis). Binary logistic regression analysis revealed that obese/overweight animals and 
animals with a pre-existing laminitis risk factor were four and eighteen times more likely to 
develop laminitis following corticosteroid treatment than animals without these, 
respectively. This was in agreement with an increased incidence of laminitis in animals with 
an endocrine disorder compared to those without within a group of animals treated with 
prednisolone (Jordan and others 2017). However, it should be remembered that breed 
(Welsh and others 2017), presence of an endocrinopathy, obesity (Coleman and others 2018) 
and previous laminitis (Wylie and others 2013b) are all risk factors for laminitis within the 
general equine population. In addition, it should be noted that the confidence intervals for 
these odds ratios were wide due to the small number of animals that developed laminitis. 
 
Anecdotally, triamcinolone is perceived to be associated with a greater risk of laminitis in 
animals treated with corticosteroids compared to other steroid types (Cornelisse and 
Robinson 2013; McIlwraith 2010). However, no association between laminitis development 
and steroid type was apparent in this study. This is in agreement with a previous study in 
which there was no association between corticosteroid preparation and the first episode of 
laminitis; prednisolone prescription was associated with 5.3 times the hazard of subsequent 
laminitis episodes only (Welsh and others 2017). 
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There was no significant association between corticosteroid dose and laminitis development. 
However it should be acknowledged that the administered doses were all within the 
recommended dose ranges for horses. Future studies evaluating the effect of dose of the 
individual steroid types would require a more rigorous, controlled experimental study design 
using higher doses.    
 
The development of laminitis during or within 14 days of the cessation of corticosteroid 
therapy was chosen as the outcome variable. This was based on previous publications which 
provided information regarding the time of onset of laminitis relative to corticosteroid 
administration. The occurrence of laminitis in animals treated with prednisolone was 
investigated and 75% developed laminitis either during or within 7 days of cessation of 
therapy (Jordan and others 2017); the remainder developed laminitis more than a month 
after cessation of therapy. Only one horse developed laminitis in association with 
triamcinolone therapy and this occurred one week after treatment (McCluskey and Kavenagh 
2004). Seven out of eight individual case reports developed laminitis either during or within 
14 days of cessation of therapy (Anon 2005; Frederick and Kehl 2000; Humber and others 
1991; Lose 1980; Ryu and others 2004; Vandenabeele and others 2004; Winfield and others 
2013). Additionally, the effects of triamcinolone on glucose metabolism in horses have been 
shown to persist for up to 8 days after administration (French and others 2000). If a horse 
developed laminitis after 14 days it was not included in the study as the time frame is too long 
to suggest a direct causal association (McGowan and others 2016). 
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The main limitation of this study was the lack of an untreated control population in study two. 
Whilst comparisons can be made with other studies with similar populations of horses and 
study one, ideally the study would have included a time-matched cohort of animals that was 
not treated with corticosteroids for a more appropriate comparison. In addition, cases of 
laminitis required a veterinary diagnosis. In first opinion practice, the condition often required 
initial identification by the owner or carer of the horse, to alert the attention of the treating 
veterinarian. It is possible that the laminitis may have gone unnoticed by the owner (Pollard 
and others 2017).  Alternatively, owners may have chosen to deal with the laminitis 
themselves or involve a paraprofessional such as the farrier rather than the veterinarian 
(Potter and others 2017). Hence the prevalence in this study may be an underestimation of 
the true prevalence 
 
It should be acknowledged that there may have been an inherent bias regarding case 
selection for corticosteroid treatment and variable recognition of pre-existing laminitis risk 
factors due to clinical judgment and variable experience of the treating veterinarian. The low 
frequency of ponies compared to horses treated with corticosteroids on both study one and 
study two may be a reflection of this due to the perceived concern that ponies are a 
phenotype that are at an increased risk of developing laminitis, especially if the animal is 
overweight or has an underlying endocrine disease.  
 
This study investigated the development of laminitis in animals treated with corticosteroids. 
However, it should be acknowledged that many of the horses included in this study were 
probably also subject to management changes, including box rest and dietary changes related 
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to their primary condition that may have increased the risk of laminitis and were not 
accounted for.  
 
In conclusion, the occurrence of laminitis in animals treated with corticosteroids in this study 
was low (0.6-1.0 %) and not dissimilar to previously published estimates of the frequency of 
veterinary-diagnosed laminitis in the GB horse and pony population (0.5%)(Wylie and others 
2013a). There was a significant association between the development of laminitis in animals 
treated with corticosteroids and breed (pony), body condition (overweight/obese) and the 
presence of pre-existing laminitis risk factors. However, breed was not retained in the final 
multivariable model and these are also risk factors for laminitis within the general horse and 
pony population. Future research to determine whether screening animals for laminitis risk 
prior to corticosteroid therapy can guide case selection and reduce the overall risk of laminitis 
in clinical practice is required.  
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Table 1: Analysis of the variables retained in the multivariable model for the development of 
acute laminitis in horses (n=1565) treated with corticosteroids 
Variable Odds Ratio 95% Confidence 
Interval 
P value 
Body condition 
(overweight/obese vs 
not) 
4.0 1.09 – 14.8 0.04 
Presence of a laminitis 
risk factor (history of 
laminitis or an underlying 
endocrinopathy vs not) 
18.23 5.05 – 65.87 <0.001 
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